Back to results

Università degli Studi di Milano

DELINEATING GUT-MEDIATED RESPONSE AMONG MELANOMA PATIENTS UNDERGOING ANTI-PD1 IMMUNOTHERAPY

Abstract

dc:description

The advent of immune checkpoint inhibition therapy markedly improved outcome for melanoma. However, response remains heterogeneous, with about half of the patients being refractory or developing relapse. Meanwhile, current knowledge on the causal link between the gut microbiota and immunotherapy response is limited to cross-sectional analyses. In this study, we perform a longitudinal study of melanoma patients undergoing immunotherapy to delineate gut changes related to response and identify gut and host factors involved. To study response-related gut microbiota changes during ICI, patients with unresectable melanoma (n=23) from two Italian hospitals were followed at baseline and over the course of anti-PD1 immunotherapy, collecting fecal and blood samples, from which we surveyed the gut microbiota, metagenome, and systemic immune profile. For validation, fecal samples from tumor-free subjects were used as reference; gut variability measures were compared against publicly available longitudinal studies; finally, multi-cohort validation was carried out on metagenomic data from baseline melanoma patients across nine studies. Our results demonstrate that the gut microbiota is distinctly stable among complete responders (CR), especially at later cycles of therapy. We identify and validate a core of longitudinally stable gut microbiota taxa in CR, comprising mostly Clostridia taxa, which also associate with markers for stability and positive systemic state. At the gut functional level, our data demonstrate a key role for Lachnospiraceae-carried flagellin genes in driving a productive anti-tumor response. Overall, we propose microbiota stability during ICI therapy as a consequential feature of an immune-beneficial Clostridia-rich gut, resulting in good response to immunotherapy.

Degree

thesis:*
Grantor dc:publisher
Università degli Studi di Milano
Year dc:date
2023

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • MACANDOG, ANGELI DOMINIQUE
Contributors dc:contributor
  • tutor: L. NEZI ; co-tutor: G. Testa ; phd coordinator: S. Minucci
  • A.D. Macandog
  • MINUCCI, SAVERIO

Subjects

dc:subject × 5

Rights

dc:rights
Statement dc:rights
  • info:eu-repo/semantics/openAccess
Language dc:language
eng

Identifiers

dc:identifier.*
OAI identifier oai:identifier
oai:air.unimi.it:2434/1019809

Chain of custody

source
Harvested from
Università degli Studi di Milano
Base URL
air.unimi.it/oai/request
Last updated
2026-07-27
Source record
OAI-PMH GetRecord
citation

MACANDOG, ANGELI DOMINIQUE. DELINEATING GUT-MEDIATED RESPONSE AMONG MELANOMA PATIENTS UNDERGOING ANTI-PD1 IMMUNOTHERAPY. Università degli Studi di Milano, 2023. https://hdl.handle.net/2434/1019809